XERS - CIK 0001867096
Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $291.85M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $291.85M | +43.7% |
| FY 2024 | $203.07M | +23.9% |
| FY 2023 | $163.91M | +48.7% |
| FY 2022 | $110.25M | +122.3% |
| FY 2021 | $49.59M | +142.7% |
| FY 2020 | $20.43M | - |
Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $291.85M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Xeris Biopharma Holdings, Inc.'s revenue grew from $20.43M to $291.85M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.